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The chemerin receptor 23 agonist, chemerin,
attenuates monosynaptic C-fibre input to
lamina I neurokinin 1 receptor expressing rat
spinal cord neurons in inflammatory pain
Allen C Dickie and Carole Torsney*
Abstract
Background: Recent evidence has shown that the chemerin receptor 23 (ChemR23) represents a novel
inflammatory pain target, whereby the ChemR23 agonists, resolvin E1 and chemerin, can inhibit inflammatory pain
hypersensitivity, by a mechanism that involves normalisation of potentiated spinal cord responses. This study has
examined the ability of the ChemR23 agonist, chemerin, to modulate synaptic input to lamina I neurokinin 1 receptor
expressing (NK1R+) dorsal horn neurons, which are known to be crucial for the manifestation of inflammatory pain.
Results: Whole-cell patch-clamp recordings from pre-identified lamina I NK1R+ neurons, in rat spinal cord slices,
revealed that chemerin significantly attenuates capsaicin potentiation of miniature excitatory postsynaptic current
(mEPSC) frequency, but is without effect in non-potentiated conditions. In tissue isolated from complete Freund’s
adjuvant (CFA) treated rats, chemerin significantly reduced the peak amplitude of monosynaptic C-fibre evoked
excitatory postsynaptic currents (eEPSCs) in a subset of lamina I NK1R+ neurons, termed chemerin responders.
However, chemerin did not alter the peak amplitude of monosynaptic C-fibre eEPSCs in control tissue. Furthermore,
paired-pulse recordings in CFA tissue demonstrated that chemerin significantly reduced paired-pulse depression in
the subset of neurons classified as chemerin responders, but was without effect in non-responders, indicating that
chemerin acts presynaptically to attenuate monosynaptic C-fibre input to a subset of lamina I NK1R+ neurons.
Conclusions: These results suggest that the reported ability of ChemR23 agonists to attenuate inflammatory pain
hypersensitivity may in part be due to a presynaptic inhibition of monosynaptic C-fibre input to lamina I NK1R+
neurons and provides further evidence that ChemR23 represents a promising inflammatory pain target.
Keywords: Dorsal horn, Lamina I, NK1R, Projection neurons, Chemerin, ChemR23, Inflammatory pain, Resolvins
Background
Inflammatory pain is a common clinical problem, how-
ever many currently used treatments, such as opioids
or cyclooxygenase (COX) inhibitors, lack efficacy and/or
exhibit undesirable side effects [1,2]. Therefore, the devel-
opment of new analgesics that are both efficacious and
lack side effects is a key challenge for pain research.
Lamina I neurokinin 1 receptor expressing (NK1R+)
neurons, a significant proportion of which are projection
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neurons [3-6], are known to be crucial for the mani-
festation of inflammatory pain hypersensitivity. Selective
ablation of these neurons by spinal administration of
a substance P–saporin conjugate significantly attenuates
hyperalgesia and allodynia in inflammatory pain mod-
els [7]. C-fibre nociceptors also play an essential role in
the development of inflammatory pain. Transgenic mice
in which Nav1.8 expressing nociceptors, which includes
the majority of C-fibres, have been selectively eliminated,
fail to develop inflammatory pain hypersensitivity [8].
Lamina I NK1R+ neurons predominantly receivemonosy-
naptic C-fibre input [9-11] and some of this input may be
© 2014 Dickie and Torsney; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
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potentiated in inflammatory pain [12]. Therefore, explor-
ing potential strategies to modulate C-fibre input to these
neurons could offer insights into novel inflammatory pain
treatments.
Recent evidence has suggested that the chemerin recep-
tor 23 (ChemR23), a Gα i associated G-protein cou-
pled receptor (GPCR), may be a promising target for
the development of novel inflammatory pain treatments.
The lipid mediator, resolvin E1 (RvE1), which acts via
ChemR23 [13], has been shown to reduce thermal and
mechanical hypersensitivity in the complete Freund’s
adjuvant (CFA) and carrageenan inflammatory pain mod-
els [14]. Furthermore, RvE1 attenuates the second phase
of the formalin response, in a manner that is compara-
ble to morphine and NS-398, a commonly used COX-
2 inhibitor, but at a substantially reduced dose [14].
Chemerin, a natural ChemR23 ligand [15,16], has also
been shown to inhibit the second phase of the forma-
lin test [14]. Interestingly, basal mechanical and thermal
thresholds and the first phase of the formalin test are unal-
tered by RvE1 administration, suggesting that strategies
which target ChemR23 may promisingly attenuate mal-
adaptive/chronic pain without altering acute protective
pain.
ChemR23 agonists have been found to have both
peripheral and central actions. In the periphery, RvE1
reduces carrageenan-induced oedema, neutrophil infil-
tration and proinflammatory cytokine and chemokine
expression [14]. Electrophysiological study of central
actions, in spinal cord slices, have established that
RvE1 and chemerin can ‘normalise’ potentiated spinal
cord responses, without altering basal synaptic trans-
mission in the dorsal horn. Specifically, application
of chemerin or RvE1 abolishes capsaicin potentia-
tion of spontaneous excitatory postsynaptic current
(sEPSC) frequency, while RvE1 has also been shown
to inhibit TNF-α mediated potentiation of sEPSC fre-
quency and NMDA currents, in unidentified lamina II
neurons [14]. However, as these findings were obtained
using sEPSC recordings from unidentified neurons, it
is not known where in the spinal cord network or
upon which neuronal subtype these central effects are
mediated.
Anatomical studies in mice demonstrate that ChemR23
is expressed both peripherally, in dorsal root ganglia
(DRG) and centrally, on the central terminals of pri-
mary afferent fibres and also on spinal cord neurons
[14]. Microarray studies, performed using rat tissue, also
report ChemR23 mRNA expression in DRG neurons and
in the dorsal horn, with expression levels being unal-
tered in CFA inflammation [17]. In mice, almost one
third of DRG neurons express ChemR23 and there is a
large degree of overlap between ChemR23 and transient
receptor potential subtype vanilloid 1 (TRPV1) channel
expression, with ∼45% of ChemR23 expressing neurons
also expressing TRPV1 and ∼60% of TRPV1 expressing
(TRPV1+) neurons also expressing ChemR23 [14]. In lam-
ina I of the dorsal horn, ChemR23 is expressed on the
central terminals of substance P containing (substance P+)
afferents [14]. Lamina I NK1R+ neurons are known to
be targeted by both TRPV1+ [18-20] and substance P+
afferents [18,21], with many C-fibres, which are the pre-
dominant type of input received by these neurons [9-11],
expressing TRPV1 and/or substance P [22-28]. There-
fore, given the co-expression of ChemR23 with TRPV1
and substance P, it is likely that some of the monosy-
naptic C-fibre input to lamina I NK1R+ neurons will
also express ChemR23. As such, it is possible that the
ability of ChemR23 agonists to attenuate inflammatory
pain hypersensitivity could in part be due to an inhi-
bition of C-fibre input to these key spinal cord output
neurons.
In this study we aimed to determine whether the
ChemR23 agonist, chemerin, could attenuate capsaicin
potentiation of miniature excitatory postsynaptic current
(mEPSC) frequency in lamina I NK1R+ neurons. Fur-
thermore, we have investigated whether chemerin can
modulate monosynaptic C-fibre input to these neurons
during inflammatory pain. While much of the interest in
targeting ChemR23 has revolved around the use of RvE1,
it should be noted that RvE1 is not commercially available,
therefore it was not possible to investigate the effect of this
compound upon the synaptic input to lamina I NK1R+
neurons.
Results
Chemerin attenuates capsaicin potentiation of mEPSC
frequency in lamina I NK1R+ neurons, but is without effect
in non-potentiated conditions
Whole-cell patch-clamp electrophysiology was used to
record mEPSCs from lamina I NK1R+ neurons in spinal
cord slices from control rats, before and during cap-
saicin application, in either the presence or the absence
of the ChemR23 agonist, chemerin (example traces in
Figure 1A and D). Bath application of 1μM capsaicin,
without chemerin, for 5 mins resulted in a significant left-
ward shift in the distribution of mEPSC inter-event inter-
vals, indicating increased frequency, in 10/12 neurons,
while in 2/12 there was no change (Kolmogorov-Smirnov
2-sample test, example shown in Figure 1B). Overall, cap-
saicin alone significantly increased mEPSC frequency in
lamina I NK1R+ neurons (P= 0.002, paired t-test, n= 12,
Figure 1C). When capsaicin was applied in the presence
of chemerin (100 ng/ml), there was a significant leftward
shift in the distribution of mEPSC inter-event intervals
in 9/10 neurons and no change in 1/10 (Kolmogorov-
Smirnov 2-sample test, example shown in Figure 1E).
Overall, capsaicin applied in the presence of chemerin
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Figure 1 Chemerin attenuates capsaicin potentiation of mEPSC frequency in lamina I NK1R+ neurons. A and D. Representative mEPSC
traces recorded before (top) and during (bottom) capsaicin (1μM) application in the absence (A) and presence (D) of chemerin (100 ng/ml). B and
E. Example cumulative probability plots demonstrate the significant leftward shift in mEPSC inter-event intervals that results from capsaicin applied
alone (B) or in the presence of chemerin (E) (both P< 0.00001, Kolmogorov-Smirnov 2-sample test). C and F. Application of capsaicin significantly
increases mEPSC frequency when applied alone (C, P= 0.002, paired t-test, n= 12) and during chemerin application (F, P= 0.008, paired t-test,
n= 10). G. Capsaicin significantly increases mEPSC frequency in the presence and absence of chemerin (P= 0.0001, 2-way repeated measures
ANOVA), however this increase is significantly attenuated by chemerin (P= 0.031, Bonferroni post-tests). All data presented as mean ± SEM, grey
points and lines in C and F indicate trajectories for individual neurons. ∗ P< 0.05, ∗∗ P< 0.01, ∗∗∗ P< 0.001.
also resulted in a significant increase in mEPSC frequency
(P= 0.008, paired t-test, n= 10, Figure 1F). However,
when the effect of chemerin on capsaicin potentiation of
mEPSC frequency was assessed, it was found that while
capsaicin significantly increased mEPSC frequency (P=
0.0001, 2-way repeated measures ANOVA, Figure 1G),
this potentiation was significantly attenuated by chemerin
(P= 0.031, 2-way repeatedmeasures ANOVA, Bonferroni
post-tests).
To assess whether chemerin altered mEPSC frequency
in lamina I NK1R+ neurons in non-potentiated condi-
tions, chemerin alone (100 ng/ml) was bath applied for
10 mins (example traces shown in Figure 2A). Chemerin
alone resulted in no change in the distribution of mEPSC
inter-event intervals in 6/11 neurons, while in 2/11 there
was a significant leftward shift and in 3/11 a signifi-
cant rightward shift (Kolmogorov-Smirnov 2-sample test,
example shown in Figure 2B). Overall, chemerin alone
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Figure 2 Chemerin alone does not alter mEPSC frequency in lamina I NK1R+ neurons. A. Representative mEPSC traces recorded prior to
(‘baseline’, left) and during chemerin (100 ng/ml) application (right). B. Example cumulative probability curve shows chemerin does not alter the
distribution of mEPSC inter-event intervals in an individual neuron (P= 0.992, 2-sample Kolmogorov-Smirnov test). C. Overall, chemerin does not
alter mEPSC frequency in non-potentiated conditions (P= 0.824, Wilcoxon, n= 11). Data presented as mean ± SEM, grey points and lines in C
indicate trajectories for individual neurons.
did not alter mEPSC frequency (P= 0.824, Wilcoxon,
Figure 2C) or amplitude (26.3±1.3 vs. 25.8±1.0 pA, P=
0.654, paired t-test, data not shown), indicating that
chemerin does not alter basal excitatory input to lamina I
NK1R+ neurons.
Characterisation of monosynaptic C-fibre input to lamina I
NK1R+ neurons
To confirm the appropriate stimulation intensities to elec-
trically activate, and thus enable the characterisation of,
primary afferent input to lamina I NK1R+ neurons, extra-
cellular compound action potential recordings were made
from dorsal roots isolated from control rats. Notably, it
has previously been established that CFA inflammation
does not alter primary afferent threshold or conduction
velocity in both adult [29,30] and juvenile rats [11]. Pri-
mary afferent components could be divided into three
distinct groups, which corresponded to Aβ-, Aδ- and C-
fibres (Figure 3A). As expected [11,29,30], the threshold
stimulus intensity differed between the primary afferent
components (Aβ < Aδ < C, P< 0.0001, 1-way ANOVA,
n= 9, Figure 3B) as did the conduction velocity (Aβ
4.37 ± 0.48 m/s, Aδ 0.83 ± 0.10 m/s, C 0.19 ± 0.01 m/s,
P< 0.0001, 1-way ANOVA, n= 9). When the stimu-
lus response relationship of the C-fibre component was
assessed, it was found that the response amplitude grad-
ually increased from an intensity of 150μA, indicating a
gradual recruitment of C-fibres, and plateaued at an inten-
sity of 400μA (Figure 3C), suggesting that the majority
of C-fibres were activated at this intensity. It has been
reported that in response to repetitive stimulation, the
slow (C-fibre) component, but not A-fibre components,
displays a frequency-dependent prolongation of latency
[30]. In agreement with these findings, when isolated dor-
sal roots were repetitively stimulated at frequencies of
1 or 2 Hz, we observed a clear prolongation of latency
in the C-fibre, but not Aδ-fibre, component (representa-
tive traces in Figure 3D), with there being a significantly
greater latency change in the C-fibre compared to the Aδ-
fibre component (P< 0.0001, 2-way ANOVA, Figure 3E).
Furthermore, 2 Hz stimulation resulted in a significantly
greater degree of latency prolongation than 1 Hz in the C-
fibre component (P< 0.0001, 2-way ANOVA followed by
Bonferroni post-tests, Figure 3E), indicating that this fea-
ture was frequency-dependent. Based on these data, 20,
100 and 500μA were used to activate the different pri-
mary afferent components in the subsequent patch-clamp
recordings and are detailed in Figure 3B.
Figure 4A shows an example of eEPSCs recorded from
a lamina I NK1R+ neuron, in a CFA spinal cord slice, that
received monosynaptic C-fibre input only. Stimulation of
the dorsal root at low-frequency (0.05Hz, duration 0.1ms,
three times, left traces) at Aβ-fibre (20μA) and Aδ-fibre
(100μA) intensities did not evoke EPSCs, whereas stim-
ulation at C-fibre intensity (500μA) clearly evoked a
response, which when stimulated at high-frequency (1 Hz,
right traces) was reliably evoked, indicating that this C-
fibre-evoked response was monosynaptic. An example of
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Figure 3 Primary afferent fibre characterisation in compound action potential recordings. A. Representative compound action potential
trace recorded from an isolated dorsal root, evoked by 500μA stimulation, illustrating the fast (Aβ), medium (Aδ) and slow (C) conducting
components (average of 10 traces shown). B. Threshold stimulus intensity of the Aβ-, Aδ- and C-fibre components, which differed significantly with
fibre type (P< 0.0001, 1-way ANOVA, n= 9). C. Stimulus response relationship for the C-fibre component. D. 1 Hz stimulation of an isolated dorsal
root resulted in a prolongation of latency in the C-, but not Aδ-fibre component. Broken lines denote the negative peak of the Aδ-/C-fibre response
during the first and last stimuli. E. Quantification of the latency prolongation demonstrated that the C-fibre, but not Aδ-fibre, component exhibited a
significant frequency dependent latency prolongation (Aδ vs. C and 1 Hz vs. 2 Hz, P< 0.0001, 2-way ANOVA). All data presented as mean ± SEM.
Dotted lines in B. indicate the dorsal root stimulation intensities (Aβ , 20μA; Aδ, 100μA; C, 500μA) used in the subsequent patch-clamp
electrophysiology studies. ∗∗∗∗ P< 0.0001.
eEPSCs recorded from a lamina I NK1R+ neuron, in a
control spinal slice, receiving monosynaptic C-fibre with
polysynaptic Aδ-fibre input is shown in Figure 4B. Low-
frequency dorsal root stimulation at Aδ-fibre, but not
Aβ-fibre, intensity evoked small ESPCs, while C-fibre
intensity additionally evoked a larger longer latency com-
ponent. When stimulated at high-frequency (2 Hz), the
Aδ-fibre response displayed failures, indicating a polysy-
naptic input, while the C-fibre input was found to be
monosynaptic as it was reliably evoked during 1 Hz
stimulation.
Chemerin attenuates monosynaptic C-fibre input to a
subset of lamina I NK1R+ neurons in inflammatory pain
To determine whether chemerin modulates monosy-
naptic C-fibre input to lamina I NK1R+ neurons in
inflammatory pain, C-fibre evoked excitatory postsy-
naptic currents (eEPSCs) were recorded in spinal cord
slices from control (untreated) and CFA treated rats,
prior to and during chemerin or vehicle application. In
control neurons, a 15 minute application of chemerin
(100 ng/ml) did not alter the peak amplitude of C-
fibre eEPSCs when compared with vehicle (P= 0.502, 2-
way repeated measures ANOVA, chemerin n= 7, vehicle
n= 8, Figure 5A), although peak amplitude significantly
declined over time (P= 0.013, 2-way repeated measures
ANOVA). Likewise, no significant difference was detected
in the peak amplitude of monosynaptic C-fibre eEPSCs
between chemerin and vehicle application in CFA neurons
(P= 0.152, 2-way repeated measures ANOVA, chemerin
n= 16, vehicle n= 7, Figure 5B), but there was a signifi-
cant reduction in peak amplitude over time (P< 0.0001,
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Figure 4Monosynaptic C-fibre input to lamina I NK1R+ neurons. A. and B. Characterisation of primary afferent input to lamina I NK1R+ neurons
receiving monosynaptic C-fibre only and monosynaptic C-fibre with polysynaptic Aδ-fibre input, respectively. Left traces show examples of ESPCs
evoked by dorsal root stimulation at Aβ- (20μA), Aδ- (100μA) and C-fibre (500μA) intensities, at low frequency (0.05 Hz). Each trace is an average of
3 traces. Right traces show examples of EPSCs evoked using higher-frequency stimulation (20μA/20 Hz; 100μA/2 Hz; 500μA/1 Hz). Each trace
comprises 20 superimposed traces.
2-way repeated measures ANOVA). However, there was a
significant interaction between these factors (P= 0.0006,
2-way repeated measures ANOVA), indicating that the
decline in peak amplitude was influenced by chemerin,
which could be indicative of chemerin affecting a subset
of neurons in inflammatory pain.
Although chemerin did not alter C-fibre eEPSCs com-
pared to vehicle when the entire population of CFA neu-
rons was considered, because ChemR23 is only expressed
on a subset of TRPV1+ and a subset of substance P+ affer-
ents [14], which is likely to include C-fibre input to lamina
I NK1R+ neurons [18-21], we hypothesised that chemerin
may only be acting upon monosynaptic C-fibre input to
a subset of these neurons. To identify this subset, lin-
ear regression analysis was performed on vehicle data to
calculate 95% prediction bands. Neurons were classified
as responders if the eEPSC peak amplitude fell below the
lower 95% prediction band for at least the final 5 mins
of chemerin treatment (example in Figure 6A). Neurons
where this did not occur were classified as non-responders
(example in Figure 6B). Using this criteria it was revealed
that in CFA inflammation, 7/16 neurons were classified
as responders, while 9/16 were non-responders. Notably,
when this criteria was applied to control neurons, only
1/7 was classified as a responder, while the remaining
neurons were non-responders. To justify this classifica-
tion and confirm that responders and non-responders
were distinct populations, frequency histograms of nor-
malised mean eEPSC peak amplitude in the final 5 mins of
chemerin/vehicle application, recorded from CFA tissue
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Figure 5 Chemerin does not alter monosynaptic C-fibre eEPSCs
in the overall lamina I NK1R+ neuronal population. A. Chemerin
(100 ng/ml) does not alter the peak amplitude of monosynaptic
C-fibre eEPSCs in control tissue (P= 0.502, chemerin n= 7, vehicle
n= 8), although there is a significant decline in peak amplitude over
time (P= 0.013). B. In tissue isolated from CFA treated rats, there is no
difference in the monosynaptic C-fibre eEPSCs between chemerin
and vehicle groups (P= 0.152, chemerin n= 16, vehicle n= 7),
although there is a significant reduction in peak amplitude over time
(P< 0.0001) and an interaction between these factors (P= 0.0006). All
statistics = 2-way repeated measures ANOVA. All data presented as
mean ± SEM.
were plotted (Figure 6C). Importantly, this clearly shows
that the distribution of the responses of chemerin respon-
ders did not overlap with either the non-responder or
vehicle groupings, validating the use of this classification.
The C-fibre eEPSC data recorded in CFA tissue
were accordingly separated into ‘responders’ and ‘non-
responders’ and compared to the vehicle group. In
the subgroup of neurons classified as non-responders,
chemerin did not alter the peak amplitude of C-fibre
eEPSCs (P= 0.802, 2-way repeated measures ANOVA,
Figure 7A, example traces in Figure 7B). In those neurons
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Figure 6 Identification of a subpopulation of chemerin-
responsive lamina I NK1R+ neurons. A. Example of a neuron
classified as a chemerin responder, because the peak amplitude of
the C-fibre eEPSCs falls below the lower 95% prediction band (95%
prediction bands designated by the upper and lower grey lines) for at
least the final 5 mins of chemerin (100 ng/ml) application. B. Example
of a lamina I NK1R+ neuron classified as a chemerin non-responder
because the peak amplitude of the C-fibre eEPSCs largely falls within
the 95% prediction bands. C. Frequency histogram of the normalised
mean eEPSC peak amplitude during the final 5 mins, demonstrating
that the distribution of the responses of chemerin responders does
not overlap with either the non-responder or vehicle groups.
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Figure 7 Chemerin attenuates C-fibre input to a subset of lamina I NK1R+ neurons in CFA inflammation. A. Chemerin has no effect on the
peak amplitude of monosynaptic C-fibre eEPSCs in the population of neurons classified as ‘non-responders’ (P= 0.802, 2-way repeated measures
ANOVA, representative traces shown in B). In this subgroup of non-responders, chemerin did not alter the distribution of actual C-fibre eEPSC peak
amplitudes (P= 0.983, paired t-test, C). D. In the subgroup of chemerin responders, chemerin significantly reduces the C-fibre eEPSC amplitude
(P= 0.001, 2-way repeated measures ANOVA, representative traces shown in E). Furthermore, in neurons classified as chemerin responders,
chemerin resulted in a significant leftward shift in the distribution of actual C-fibre eEPSC peak amplitudes (P= 0.028, paired t-test, F). Example traces
show an average of 3 sweeps, baseline and chemerin traces recorded at points ‘a.’ and ‘b.’ respectively, denoted by arrows on relevant graphs.
Vehicle n= 7, chemerin responders n= 7, chemerin non-responders n= 9. Data displayed as mean ± SEM. ∗ P< 0.05, ∗∗ P< 0.01, ∗∗∗ P< 0.001.
classified as responders, application of chemerin signif-
icantly attenuated the peak amplitude of the monosy-
naptic C-fibre eEPSCs in these neurons (P= 0.001,
2-way repeated measures ANOVA, Figure 7D, exam-
ple traces in Figure 7E). Post-tests specifically revealed
that chemerin significantly inhibited the peak amplitude
of the monosynaptic C-fibre eEPSCs during the final
10 mins of chemerin application (P< 0.05 to P< 0.001, 2-
way repeated measures ANOVA, Bonferroni post-tests).
Importantly, the input resistance of both responder and
non-responder groups was stable throughout the record-
ing period (no significant change with respect to time,
P= 0.392, 2-way ANOVA). When the distribution of the
actual mean peak amplitude ofmonosynaptic C-fibre eEP-
SCs, recorded in the 5 mins prior to and the final 5 mins
of chemerin application, was compared, it was similarly
found that chemerin significantly altered the eEPSC peak
amplitude distribution in responders (P= 0.028, paired t-
test, Figure 7F), but not non-responders (P= 0.983, paired
t-test, Figure 7C).
Chemerin presynaptically inhibitsmonosynaptic C-fibre input
to a subset of lamina I NK1R+ neurons in inflammatory pain
Previous data have suggested that the ChemR23 ago-
nist, RvE1, inhibits potentiated spinal cord responses via
both pre and postsynaptic mechanisms [14]. Therefore,
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to determine the site of action of the chemerin inhibi-
tion of monosynaptic C-fibre input to lamina I NK1R+
neurons seen here, paired-pulse recordings were con-
ducted in a subset of neurons from CFA treated rats prior
to (‘baseline’) and during chemerin application. Paired-
pulse stimulation of monosynaptic C-fibre input to lamina
I NK1R+ neurons resulted in paired-pulse depression
(PPD) (example traces in Figure 8A). In neurons classi-
fied as responders, chemerin significantly increased the
paired-pulse ratio (PPR) (P= 0.031, 2-way repeated mea-
sures ANOVA, Bonferroni post-tests, Figure 8B), indi-
cating a significant decrease in PPD. In non-responders,
chemerin did not alter the PPR (P>0.999, 2-way repeated
measures ANOVA, Bonferroni post-tests). These find-
ings strongly suggest that chemerin acts presynapti-
cally to inhibit monosynaptic C-fibre input to a subset
of lamina I NK1R+ neurons. Furthermore, the exam-
ple traces in Figure 8A were obtained from a lamina I
NK1R+ neuron which received both monosynaptic C-
fibre and polysynaptic Aβ-fibre input. However, chemerin
did not alter the amplitude of this polysynaptic input
(data not shown), further supporting a presynaptic site
of chemerin action, given that a postsynaptic effect
would likely influence the response to both types of
input.
Discussion
It is known that ChemR23 agonists can alleviate hyper-
sensitivity in animal models of inflammatory pain through
both peripheral and central mechanisms [14]. These
include a reduction in peripheral inflammation and
a normalisation of potentiated spinal cord responses,
respectively. In terms of central mechanisms, electro-
physiological recordings from unidentified lamina II dor-
sal horn neurons have demonstrated that the ChemR23
agonists, RvE1 and chemerin, attenuate capsaicin poten-
tiation of sEPSC frequency. However, as these findings
were obtained using sEPSC recordings in unidentified
neurons it is not known where in the spinal cord network
or upon which neuronal subtypes that these effects are
mediated. In this study we have investigated the ability of
chemerin to modulate excitatory input to lamina I NK1R+
neurons following capsaicin potentiation and CFA inflam-
mation. Our results have novelly revealed that chemerin
Responders Non-responders
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0 Baseline
Chemerin
*
Pa
ire
d-
pu
ls
e 
R
at
io
B
PPR = 0.57
Chemerin
PPR = 0.76
Interstimulus interval = 500ms
Baseline
20
0p
A
100ms
A
Figure 8 Chemerin reduces paired-pulse depression of monosynaptic C-fibre input to lamina I NK1R+ neurons. A. Representative EPSC
traces evoked by C-fibre paired-pulse stimulation in a chemerin responder recorded before (left, blue trace) and during (right, red trace) chemerin
application (average of 6 sweeps shown), where chemerin has increased the paired-pulse ratio/decreased paired-pulse depression. B. In neurons
classified as chemerin responders, application of chemerin significantly increases the paired-pulse ratio/decreases paired-pulse depression
(P= 0.031, 2-way repeated measures ANOVA, followed by Bonferroni post-tests). Responders n= 5, non-responders n= 6. Data presented as
mean ± SEM. ∗ P< 0.05.
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can attenuate capsaicin potentiation of mEPSC frequency
in lamina I NK1R+ neurons and presynaptically reduce
monosynaptic C-fibre input to a subset of these neurons in
inflammatory pain. Notably, chemerin was without effect
in non-potentiated/control conditions. Given the essen-
tial role of lamina I NK1R+ neurons in the manifestation
of inflammatory pain [7], which is driven by C-fibres [8],
the chemerin attenuation of monosynaptic C-fibre input
to these neurons suggests that the reported ability of
ChemR23 agonists to attenuate inflammatory pain hyper-
sensitivity may in part be due to presynaptic inhibition
of monosynaptic C-fibre input to these key spinal cord
output neurons.
We have demonstrated that chemerin can signifi-
cantly reduce, but not eliminate, capsaicin potentiation of
mEPSC frequency in rat lamina I NK1R+ neurons. How-
ever, Xu et al. [14] report that chemerin, at the same
dose used here, can completely prevent capsaicin potenti-
ation of sEPSC frequency in unidentified mouse lamina II
neurons. This difference likely reflects the different con-
centrations of capsaicin employed, 1μM in the present
study, which resulted in a ∼44-fold increase in frequency,
vs. 100 nM used by Xu et al. [14], which increased fre-
quency by only 2-fold. We did investigate use of 100 nM
capsaicin, but found that this concentration did not reli-
ably potentiate mEPSC frequency in lamina I NK1R+
neurons (data not shown). This dissimilarity may also
reflect the different species employed, rat vs. mouse, dif-
ferent cell types targeted, lamina I NK1R+ neurons vs.
unidentified lamina II neurons or the different recording
approach, mEPSC vs. sEPSC recording, employed. Other
groups have demonstrated that 100 nM capsaicin can
potentiate mEPSC frequency in unidentified lamina I/II
neurons [31,32], however potentiation of mEPSCs in lam-
ina I NK1R+ neurons has only been reported using 1μM
capsaicin [19]. Interestingly, Labrakakis and MacDermott
[19] report that 73% of lamina I NK1R+ neurons display
an increase in mEPSC frequency in response to 1μMcap-
saicin, which is comparable to our findings, that 83% of
neurons had capsaicin-sensitive input.
On the basis of anatomical expression data [14] we
hypothesised that ChemR23 would be expressed on a sub-
set of monosynaptic C-fibre inputs to lamina I NK1R+
neurons. Indeed we provide supporting functional evi-
dence for this expression pattern through our novel
demonstration that chemerin presynaptically attenuates
monosynaptic C-fibre input to a subset of these neu-
rons in inflammatory pain. To unequivocally demonstrate
that the chemerin effects reported here are mediated
via ChemR23, we would ideally have shown blockade
by a ChemR23 antagonist, but this was not possible
as no such ligand is commercially available. Pertussis
toxin (PTX), an inhibitor of Gα i coupled GPCRs, the
receptor family to which ChemR23 belongs, has been
used by others to inhibit the RvE1 attenuation of cap-
saicin potentiated input in unidentified lamina II neu-
rons [14]. While this approach could have been used
to provide additional confirmation that the actions of
chemerin were mediated by ChemR23, PTX inhibition of
the chemerin response would only indicate that chemerin
acted via a Gα i coupled GPCR and not ChemR23
specifically.
ChemR23 agonists are proposed to reduce inflamma-
tory pain in part by normalising potentiated spinal cord
responses [14,33]. In the present data, chemerin reduced
monosynaptic C-fibre input to a subset (∼44%) of lam-
ina I NK1R+ neurons in CFA tissue but was without
effect in control tissue. Interestingly, electrical stimula-
tion of monosynaptic C-fibre input to lamina I projection
neurons, that are likely to be NK1R+ neurons, in a man-
ner which mimics the spontaneous firing pattern seen
during inflammatory pain, results in the potentiation of
C-fibre input to only a subset of these neurons [12]. It
could therefore be hypothesised that neurons classified as
chemerin responders were the subset that received poten-
tiated C-fibre input. We therefore investigated whether
there was a correlation between the initial peak amplitude
of monosynaptic C-fibre eEPSCs (with greater amplitudes
possibly signifying potentiated inputs) and the magnitude
of the chemerin mediated change in peak amplitude. Our
results found there to be no correlation between the ini-
tial eEPSC peak amplitude and the amplitude change (data
not shown), however it should be recognised that this
finding cannot confirm or refute the possibility that neu-
rons classified as chemerin responders were those that
received potentiated input, as it is not possible to directly
distinguish potentiated inputs in this kind of population
comparison study. Moreover, when the peak amplitude
of monosynaptic C-fibre eEPSCs are compared between
control and CFA tissue there is no significant potenti-
ation observed overall (data not shown) as previously
reported [11].
It has previously been established that ChemR23 ago-
nists do not alter acute pain sensitivity and have no
effect upon sEPSC frequency, in unidentified lamina II
neurons, in non-potentiated conditions [14]. In accor-
dance, we have shown that chemerin does not alter basal
mEPSC frequency or amplitude in lamina I NK1R+ neu-
rons or the peak amplitude of monosynaptic C-fibre
eEPCSs in these neurons in control tissue. It is pro-
posed that ChemR23 activation reduces inflammatory
pain hypersensitivity by normalising potentiated spinal
cord responses, as opposed to a general reduction in sen-
sory transmission [14,33], for which our findings provide
additional support.
ChemR23 activation is proposed to normalise spinal
cord inflammatory pain potentiation by inhibition of
the extracellular signal-regulated kinase (ERK) pathway,
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which is key for central sensitisation [34], both presy-
naptically in the central terminals of primary afferents
and postsynaptically in dorsal horn neurons [14]. Inhibi-
tion of ERK, with the mitogen-activated protein kinase
kinase inhibitors PD98059 and U0126, prevents cap-
saicin potentiation of sEPSCs, while application of RvE1
reduces capsaicin/TNF-α driven ERK phosphorylation in
DRG cultures [14]. Therefore, the chemerin attenuation
of capsaicin potentiated mEPSC frequency and chemerin
mediated presynaptic inhibition of monosynaptic C-fibre
inputs in inflammatory pain, reported here, may result
from blockade of ERK mediated glutamate release from
central terminals. Chemerin may also mediate its effects
via inhibition of TRPV1, which is crucial for inflamma-
tory pain [35,36], as RvE1 is a highly potent inhibitor
of TRPV1, with different resolvins interestingly differ-
entially modulating different TRP channels via GPCR
activation [37,38].
Chemerin is a natural ChemR23 ligand [15,16] andwhile
it is currently unclear which cell types are responsible
for its endogenous production and release, endothelial
cells, keratinocytes, chondrocytes, platelets and osteo-
clasts have all been proposed as possible sources [39-44].
Chemerin plays a key role in a number of physiological
processes including adipocyte generation and metabolism
[45] and the chemotaxis of macrophages and dendritic
cells [16]. However, it is not currently known whether
endogenous chemerin plays any role in the modulation of
inflammatory pain.
It is worth noting that chemerin is known to dis-
play high affinity binding with receptors other than
ChemR23, namely the chemokine (C-C motif ) receptor-
like 2 (CCRL2) and G protein-coupled receptor 1 (GPR1),
however these receptors are thought to play a limited role
in cell signalling. Current evidence suggests that CCRL2
is not involved in cell signalling but may play a func-
tional role in presenting chemerin to ChemR23 [40,46,47].
Interestingly, CCRL2 is known to be expressed in the
spinal cord and wider CNS, predominantly in microglia
[48]. Binding of chemerin to GPR1 results in receptor
internalisation and signalling, but this signalling is weak
[49] and it has been speculated that GPR1 may act as
a decoy receptor [40]. There is evidence that GPR1 is
expressed in the CNS [50-53], however spinal cord expres-
sion has not been investigated. It is possible, therefore,
that inflammation-induced changes in the expression of
either of these receptors could have influenced the results
presented here.
While the evidence presented here supports the work
by Xu et al. [14] which revealed that drugs which target
ChemR23 may be effective in the treatment of inflam-
matory pain, it is worth noting that chemerin or RvE1
may have limited therapeutic potential given that they
are not metabolically stable and are rapidly inactivated in
vivo [33,54,55]. Interestingly, a stable analogue of RvE1,
19-(p-fluorophenoxy)-RvE1, has been shown to effectively
reduce thermal hypersensitivity in the CFA inflammatory
painmodel for an extended time period compared to RvE1
[14]. Stable chemerin analogues have been developed [56],
however their use has not yet been investigated in mod-
els of inflammatory pain. Further research into the use
of these or new stable analogues of ChemR23 agonists
should further establish ChemR23 as a promising target
for the treatment of inflammatory pain.
Conclusions
This study demonstrates that the ChemR23 agonist,
chemerin, can attenuate capsaicin potentiation of mEPSC
frequency in lamina I NK1R+ neurons, but is with-
out effect in non-potentiated conditions. Furthermore,
chemerin presynaptically inhibits monosynaptic C-fibre
input to a subset of these neurons in inflammatory pain,
but does not alter C-fibre eEPSCs in control condi-
tions. These findings suggest that the reported ability of
ChemR23 agonists to attenuate inflammatory pain hyper-
sensitivity could in part be due to the inhibition of C-fibre
input to these key spinal cord output neurons and pro-
vides further evidence that ChemR23 represents a promis-
ing target for the development of novel inflammatory pain
treatments.
Methods
Animals
All procedures were approved by the University of Edin-
burgh Ethical Review Committee and carried out in accor-
dance with the UK Animals (Scientific Procedures) Act
1986. Juvenile Sprague Dawley rats of both sexes (approxi-
mately postnatal day 21 [P21]; the University of Edinburgh
Biological Research Resources, Edinburgh UK) were used
in all experiments. No differences were found between
male and female rats so all data presented are a combina-
tion of both sexes. Animals were housed in cages at 21°C
and 55% relative humidity, with a 12 h light-dark cycle.
Food and water were provided ad libitum.
Inflammatory pain model
Complete Freund’s adjuvant (CFA, 0.5 mg/ml saline) was
injected into the intraplantar surface of the left hind-
paw (1μl/g body weight) under isoflurane anaesthesia
at ∼P18, 2–6 days prior to electrophysiological record-
ings at ∼P21. This procedure has been shown to pro-
duce persistent peripheral inflammation and behavioural
hypersensitivity in juvenile rats [11].
Spinal cord slice preparation
CFA treated or naïve untreated (control) rats were anaes-
thetised with isoflurane and decapitated. Spinal cords, in
some cases with dorsal roots attached, were removed and
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were initially placed in ice-cold dissection solution. The
lumbar (L4/L5) segment was embedded in an agarose
block and cut into transverse slices (350μm).Where slices
with dorsal roots attached were cut, dorsal root ganglia
were removed and only the left dorsal roots were used
in CFA treated rats. Slices were incubated at 36–37°C for
1 h in oxygenated recovery solution after which they were
incubated at room temperature for 30 mins with 35 nM
tetramethylrhodamine conjugated substance P (TMR-SP),
as described previously [10,11,19]. Slices were allowed
to recover for a further 1 h at room temperature prior
to recording. Slices were transferred to the recording
chamber of an upright microscope (Zeiss), equipped with
fluorescence for the identification of TMR-SP labelled
(TMR-SP+) neurons and infrared-differential interference
contrast (IR-DIC) for electrophysiological recordings and
were continually perfused with oxygenated Krebs solu-
tion (1–2 ml/min) at room temperature. The composi-
tion of the 95% O2/5% CO2 saturated Krebs solution is
as follows (in mM): 125 NaCl, 2.5 KCl, 26 NaHCO3,
1.25 NaH2PO4, 25 glucose, 1 MgCl2, 2 CaCl2, pH7.4.
Recovery solution was identical to Krebs but with 6 mM
MgCl2 and 1.5 mM CaCl2. Dissection solution was the
same as recovery but with the addition of 1 mM kynurenic
acid.
Our technique for pre-identifying NK1R+ neurons is
expected to have little impact on the synaptic activity
we are studying. TMR-SP is one of the least biologically
active of fluorescence conjugated substance P analogues
and does not inhibit neuronal M-type K+ current at
the nanomolar concentration used in our study, although
it does elevate calcium in Chinese hamster ovary cells
expressing NK1 receptor [57]. Moreover, this TMR-SP
labelling approach has been validated in a previous study
of spinal NK1R+ neurons [20]. However, we cannot rule
out the possibility that this labelling approach may inter-
fere with the response of these neurons to chemerin.
Retrograde labelling of these likely projection neurons
[12,58] is an alternative approach that could be employed
to address this potential issue.
Patch-clamp recording
Whole-cell patch-clamp recordings were made from
‘identified’ neurons in the lamina I region of the dorsal
horn. All recordings were made at a holding potential
of -70 mV and junction potential was corrected prior
to recording. Data were recorded and acquired with an
Axopatch 200B amplifier and pClamp 10 software (Molec-
ular Devices). Data were filtered at 5 kHz and digitised at
10 kHz.
mEPSC recording
mEPSCs were recorded from lamina I NK1R+ neu-
rons in spinal slices from control tissue with dorsal
roots removed, in the presence of 0.5μM TTX, 10μM
bicuculline and 1μM strychnine. The intracellular solu-
tion composition was as follows (in mM); 110 K-
methanesulfonate, 10NaCl, 10 EGTA, 1 CaCl2, 10HEPES,
5 Mg2+-ATP, 0.5 Na+-GTP, pH adjusted to 7.2 with
KOH, osmolarity 290 mOsm. 1μM Alexa Fluor 488
hydrazide was also included in the recording pipette to
confirm that the TMR-SP+ neuron detected under fluo-
rescence was the same as that targeted for recording under
IR-DIC.
Baseline mEPSCs were recorded for 5 mins, following
which the TRPV1 agonist, capsaicin (1μM), was bath
applied for 5 mins to pharmacologically potentiate exci-
tatory input [59]. Potentiation was assessed by comparing
mEPSCs recorded at baseline (final 2 mins) and during
capsaicin application (final 2 mins). To assess whether
chemerinmodulates this capsaicin potentiation, chemerin
(100 ng/ml) was bath applied for 10 mins prior to and
throughout capsaicin application, in a separate group of
lamina I NK1R+ neurons. Two separate neuronal popu-
lations were used, rather than a within cell comparison,
because capsaicin potentiation of mEPSC frequency does
not return to baseline, even following a long wash period
(data not shown), as is reported elsewhere [31] and it is
known that repeated capsaicin applications results in a
progressive reduction in capsaicin response [31,60]. The
effect of chemerin upon mEPSCs in non-potentiated con-
ditions was similarly assessed by applying chemerin alone.
In all cases the final 2 mins of baseline/drug application
was analysed using Mini Analysis (Synaptosoft), mEPSC
events were automatically detected by the software and
were then accepted or rejected following further visual
examination.
eEPSC recording
eEPSCs were recorded from lamina I NK1R+ neurons in
spinal cord slices, with dorsal roots attached, from con-
trol and CFA treated rats. Monosynaptic C-fibre input
was identified by stimulation of the dorsal root with a
suction electrode, as described previously [10,11]. The
dorsal root was stimulated (3 times) at low frequency
(0.05 Hz), using an ISO-Flex stimulus isolator (A.M.P.I
Intracel), at 20, 100 and 500μA (0.1 ms stimulus dura-
tion) to activate Aβ-, Aδ- and C-fibre inputs, respec-
tively. C-fibre eEPSCs were identified as longer latency
components evident at 500μA (but not 20 or 100μA)
stimulation intensity. C-fibre eEPSCs were considered
monosynaptic if when stimulated (20 times) at the higher
frequency of 1 Hz they displayed no synaptic failures,
regardless of whether there was latency variability [30]. A
500μA stimulation intensity was employed for C-fibres,
as compound action potential recordings demonstrated
that the slow C-fibre component appeared to be maxi-
mally recruited at this intensity (Figure 3C). It is possible
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that higher stimulation intensities could recruit additional
C-fibres, but this seems unlikely given that this 500μA
intensity reveals monosynaptic C-fibre input to a sim-
ilar proportion of these neurons [11] as that observed
in experiments employing stimulation intensities greater
than 800μA [9]. The intracellular solution was composed
of the following (in mM): 120 Cs-methylsulfonate, 10 Na-
methylsulfonate, 10 EGTA, 1 CaCl2, 10HEPES, 5QX-314-
Cl [2(triethylamino)-N-(2,6-dimethylphenyl) acetamine
chloride] and 2Mg2+-ATP, pH adjusted to 7.2 with CsOH,
osmolarity 290 mOsm. Additionally, 1μM Alexa Fluor
488 hydrazide was included in the recording pipette.
To assess the ability of chemerin to modulate monosy-
naptic C-fibre input to lamina I NK1R+ neurons, C-fibre
EPSCs were evoked at 500μA (0.05 Hz, 0.1 ms stimulus
duration) for 10 mins (‘baseline’), followed by a further
15 mins in the presence of either chemerin (100 ng/ml)
or vehicle (Krebs only). Peakmonosynaptic C-fibre eEPSC
amplitude was measured for each sweep and the mean
peak amplitude per minute was calculated. All data were
normalised to minute 2 because in many neurons there
was a large degree of run-down in the eEPSC peak ampli-
tude between minute 1 and minute 2, after which the
response generally stabilised (data not shown).
We hypothesised that chemerin would modulate pri-
mary afferent input to a subset of lamina I NK1R+ neu-
rons, given that ChemR23 is only expressed on a subset of
TRPV1+ and a subset of substance P+ afferents [14]. To
identify this subgroup, linear regression analysis was per-
formed on vehicle data to calculate 95% prediction bands.
A neuron was classified as a responder if the eEPSC peak
amplitude fell below the lower limit of the 95% prediction
bands for at least the final 5 mins of chemerin applica-
tion. To evaluate the validity of this classification method
and to assess whether responders and non-responders
were two distinct subpopulations, frequency histograms
of normalised mean peak amplitude in the final 5 mins
of chemerin/vehicle application were plotted. Addition-
ally, histograms of actual mean peak amplitude in the
5 mins prior to and the last 5 mins of chemerin appli-
cation were plotted for both chemerin responders and
non-responders.
To determine the pre/postsynaptic nature of chemerin
effects, paired-pulse recordings were conducted in a sub-
set of neurons in CFA tissue. Monosynaptic C-fibre eEP-
SCs were recorded at baseline and in the presence of
chemerin as described above, however rather than a sin-
gle stimulus being applied every 20 seconds (0.05 Hz)
the dorsal root was stimulated twice in close succession
(500 ms interstimulus duration) every 20 seconds. PPR,
of the monosynaptic C-fibre component, was calculated
for the 5 mins prior to (‘baseline’) and the final 5 mins of
chemerin application, as PPR = mean eEPSC peak ampli-
tude 2/mean eEPSC peak amplitude 1, so as to correct
for misleading facilitation that can be caused by random
amplitude fluctuations [61].
Isolated dorsal root preparation
Spinal cords were removed from control rats, in the man-
ner described above and lumbar (L4/L5) dorsal roots, with
dorsal root ganglia removed, were cut near to the dorsal
root entry zone and placed in oxygenated recovery solu-
tion, at a temperature of 36–37°C, for 1 h and were then
maintained at room temperature prior to recording.
Compound action potential recording
Compound action potential recordings were made from
isolated dorsal roots using two glass suction electrodes,
placed at either end of the dorsal root. To determine
the electrical activation threshold of the different pri-
mary afferent components, dorsal roots were stimulated
10 times at a frequency of 0.2 Hz (0.1 ms duration) with
an ISO-flex stimulus isolator (A.M.P.I. Intracel) at the fol-
lowing intensities (in μA): 1, 2, 3, 4, 5, 7.5, 10, 15, 20, 25,
30–100 (in 10μA steps) and 150–500μA (in 50μA steps)
[11]. The main components of the compound action
potentials were differentiated as fast (Aβ), medium (Aδ)
and slow (C) conducting components, each with a char-
acteristic triphasic (positive-negative-positive) response
(Figure 3A). Threshold stimulus intensities for the com-
ponents were defined as the lowest stimulation intensity
at which the negative component of the triphasic response
was first clearly identifiable. The conduction velocity of
each component was calculated based on the latency to
the negative peak of the response, at 20, 100 and 500μA
for Aβ-, Aδ- and C-fibres, respectively. The amplitude
of the C-fibre component was measured as the distance
between the negative and positive peaks, at 500μA. To
assess latency prolongation in the Aδ- and C-fibre com-
ponents, dorsal roots were stimulated 20 times at 1 and
2Hz (500μA intensity, 0.1ms duration) and the difference
between the latency measured at stimulus 1 and stimulus
20 was calculated. Data were acquired and recorded using
a Cygnus ER-1 differential amplifier (Cygnus Technologies
Inc.) and pClamp 10 software (Molecular Devices).
Statistical analysis
All data were assessed for normality using D’Agostino and
Pearson omnibus normality tests, to determine whether
it was appropriate to use parametric or non-parametric
statistical tests and are presented as mean ± SEM. All sta-
tistical analysis was performed using Prism 6 (Graphpad
Software).
Materials
All chemicals were obtained from Sigma except; bicu-
culline (Tocris), TMR-SP (Enzo Life Sciences), Alexa Fluor
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488 hydrazide (Molecular Probes), chemerin (R&D Sys-
tems), QX-314-Cl and TTX (Alomone Labs).
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